米系製è¬ä¼ç¤¾BMSã®SGLT2
cialis, Dapagliflozinã®Ph 3ãã¼ã¿ã¼ãçºè¡¨ããã¾ãã。
Results from a 24-week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint
ã¨ããã®ã§、ä¸æãè¡ã£ã¦ããããã§ã。 å¾æ¥、48-week follow
(
Read more... )